Repetitive transcranial magnetic stimulation (rTMS) is approved by the US Food and Drug Administration (FDA) for treatment resistant depression (TRD), and presumably works by modulating brain circuitry. A new meta-analysis focuses specifically on using rTMS as augmentation to antidepressants in patients with TRD.
A recent study out of London found that users of high potency cannabis (also known as “skunk” weed) are three times more likely to experience a psychotic episode than those who never use cannabis; and those who use it daily are at a fivefold increased risk.
A recent study tested an intensive weight loss program in a large group of psychiatric patients. The results were…well, read on and you decide whether they were impressive.
We’ve known for some time that if your patient has a parental history of a mood disorder or suicide attempt, his or her risk of a suicide attempt increases, and a new study adds some more information that might help us prevent bad outcomes.
A new study on the safety and efficacy of Symbyax (olanzapine/fluoxetine combination or OFC) in kids with bipolar I depression is in press and will be published soon.
Adolescents are commonly prescribed anti-anxiety or sleep medications, which is often reasonable, given the efficacy of these agents. We often worry about abuse potential, but we’ve had little data to tell how much we should worry, until now. It turns out that we may be prodding some of these teens down the road toward addiction.
Exercise is good for the brain as well as the body—we’ve known for several years that this is true for adults, but a new study indicates it’s true for children, too.
There is disagreement about the causes of this increased incidence of autism. Debate has focused on whether the rise in cases is an artifact caused by increased diagnosis and reporting, or if there is some unknown pathogenic factor in the environment that is causing an actual increase in new cases. A new study out of Denmark provides support for the artifact argument.